Among other disease areas, Boehringer Ingelheim is concentrating research efforts and investment in cardio–renal–metabolic (CRM) diseases – a group of interconnected conditions affecting the heart, kidneys, and the metabolic system. More than 1 billion people worldwide are living with CRM diseases such as obesity, type 2 diabetes, chronic kidney disease, liver disease, heart failure, and cardiovascular disease. Despite significant improvements in life expectancy over the last decades, CRM diseases are still amongst the leading causes of death globally – and their prevalence is expected to continue to rise.
Due to the interconnectivity of the CRM systems, people are often impacted by multiple health conditions, posing an increased physical and emotional burden. Boehringer Ingelheim is addressing these challenges by taking a holistic approach to the management of CRM conditions. While the onset of one disease can increase the risk of developing another, improvement in one disease can have additional benefits in others. Considering this, Boehringer Ingelheim is exploring synergies between disease mechanisms and pathways to deliver the next wave of innovative therapies aiming to restore the balance between the interconnected CRM systems, reducing the risk of serious complications, thereby improving the outcomes of people living with CRM diseases.
Our legacy in cardio–renal–metabolic diseases
Boehringer Ingelheim’s significant expertise and leadership in CRM diseases is evidenced by our track record of excellence in research and landmark clinical trials, which have resulted in important achievements in recent years, especially in thromboembolic diseases, type 2 diabetes, heart failure, and chronic kidney disease. Boehringer Ingelheim developed the first pharmacotherapy for type 2 diabetes that demonstrated substantial cardiovascular benefits in a cardiovascular outcomes trial. This has paved the way for a shift towards a holistic view on CRM diseases, including heart failure and chronic kidney disease. By building on our long-standing legacy and deep knowledge, Boehringer Ingelheim is developing a portfolio of novel compounds that address CRM conditions with enduring high unmet medical need. One prominent CRM condition that is being researched is obesity, a metabolic and multifactorial disease at the center of CRM diseases.
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.
Novo Nordisk is a leader in obesity care, helping advance the understanding and management of obesity as a chronic disease. Changing Obesity™ is Novo Nordisk’s long-term commitment to – together with our partners – improve the lives of people with obesity, by changing how the world sees, prevents and treats obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 43,200 employees in 80 countries and markets its products in more than 170 countries.
|Contact||: Jakob Jakobsen|
|P||: +45 3079 0781|
|E||: [email protected]|
Currax Pharmaceuticals LLC
Currax Pharmaceuticals LLC is a specialty biopharmaceutical company focused on enhancing the lives of patients worldwide by expanding access to life-changing medications that treat diseases such as obesity. Currax distributes a range of both branded and generic pharmaceutical products. For more information, please visit our website: www.curraxpharma.com
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company committed to transform the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases by rapidly advancing care and precision medicines addressing the root cause. Our science is dedicated to the understanding of hyperphagia and severe obesity caused by genetic variants leading to an impaired MC4R pathway. For more information about the science and our solutions, please visit our website: www.path4hcps.com
VIVUS is a biopharmaceutical company committed to advancing innovative clinical therapies. With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. We are a focused organization with the expertise and insights to advance innovative new therapies. VIVUS manufactures Qsymia® (phentermine and topiramate extended-release) CIV and PANCREAZE® (pancrelipase) delayed-release capsules.
We are a medium-sized company which develops and markets high-quality pharmaceutical products. As manufacturer of medical devices with a wide expertise, we are strongly set close to Frankfurt/Main, Germany and count with a distribution network in more than 60 countries, both EU and EFTA.
Corporate strengths such as high quality standards, continuous innovation and the commitment of our employees constitute the basis for our leadership position in the dietetic segment in German pharmacy trade.
Certmedica has core competences in developing and marketing high quality standard medical devices throughout Europe. Additionally to the medical devices standards, we observe the GMP and GCP guidelines as they are applied by the pharmaceutical industry. Certmedica’s quality system conforms to the highest standards in the pharmaceutical industry.
COSMED, an Italian company established in 1980, designs, manufactures, and sells worldwide diagnostic medical devices to assess Cardiopulmonary and Metabolic functions and Body Composition, addressing the needs of Health Care and Research public and private organizations and professionals operating in the Hospital, Primary Care, Sport Science and Human Performance, and Health and Wellness markets.
COSMED medical devices are grouped into five Product Lines:
- Cardiopulmonary Exercise Testing
- Indirect Calorimetry
- Pulmonary Function Testing
- Body Composition
COSMED employs worldwide more than 200 people, with over 20 mechanical, electronic and software engineers engaged in R&D. Its headquarters are in Rome (Italy) and it has two plants located in Italy and USA.
Direct operations, through its fully owned subsidiaries, are held in Australia, Denmark, France, Germany, Hong Kong, Netherland, Switzerland, and USA, and with over 80 Business Partners, are covered more than 100 countries.
Accuracy, reliability and duration of diagnostic medical devices and the innovative software platform OMNIA, worldwide superior customer care, first class technical support, effective training services, along with regular software updates and guaranteed availability of original spare parts and supply of consumables, guarantee COSMED customers to preserve and exploit their investments over time.